Gut microbiota signatures in preterm infants correlate with neurodevelopmental impairment risk at three months corrected age.
This prospective, matched, longitudinal multi-omics study enrolled 60 preterm infants to investigate associations between early biological markers and subsequent neurodevelopmental outcomes. The cohort was stratified into high-risk and low-risk groups based on neurodevelopmental impairment status at follow-up. The primary objective was to determine if specific gut microbiota and metabolome signatures could predict neurodevelopmental impairment risk.
At three months corrected age, no difference in gut microbiome diversity was observed between the high-risk and low-risk groups. However, taxonomic composition differed significantly; the low-risk group was enriched with Akkermansia muciniphila, whereas the high-risk group was dominated by Klebsiella variicola. Functional pathway analysis revealed that the high-risk group exhibited enrichment for bacterial virulence, stress response, and human neurodegenerative disease pathways, while the low-risk group showed expansion of core biosynthesis pathways. Metabolomics profiles indicated impaired amino acid metabolism and aberrant neuroactive pathway enrichment in the high-risk group.
Integrated network analysis linked Akkermansia muciniphila and co-varying glycerophospholipids to superior neurodevelopmental scores. Conversely, Klebsiella variicola and triterpenoids formed a dysbiotic hub associated with higher risk. Meconium features also correlated with three-month neurobehavioral scores. No adverse events, serious adverse events, discontinuations, or tolerability issues were reported, as these data were not collected or reported in the study. The study notes that specific longitudinal multi-omics signatures predictive of neurodevelopmental impairment risk in preterm infants are currently poorly defined.
These signatures offer novel targets for early risk prediction and potential microbiome-targeted interventions. However, clinicians must recognize that these biomarkers are early and not yet validated for routine practice. The specific longitudinal multi-omics signatures predictive of neurodevelopmental impairment risk in preterm infants remain poorly defined, limiting immediate clinical application.